Table 1 Characteristics of study subjects
Characteristics of study subject (n = 2998) | Female (n = 2097) | Male (n = 901) | Total (n = 2998) | P value (chi square test) | ||||
|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | |||
Age (mean (SD)) | 20.13 (mean) | 1.74 (SD) | 20.56 (mean) | 2.01 (SD) | 20.26 (mean) | 1.84 (SD) | (Wilcoxon test) | |
Degree | Undergraduate | 2085 | 99.43% | 890 | 98.78% | 2975 | 99.23% | 0.019 |
Master | 12 | 0.57% | 8 | 0.89% | 20 | 0.67% | ||
Doctoral | 0 | 0.00% | 3 | 0.33% | 3 | 0.10% | ||
Residence | School dormitory | 219 | 10.44% | 114 | 12.65% | 333 | 11.11% | 0.100 |
Rent a house outside | 742 | 35.38% | 331 | 36.74% | 1073 | 35.79% | ||
Live with family | 1136 | 54.17% | 456 | 50.61% | 1592 | 53.10% | ||
Field of study | Non-medical | 669 | 31.90% | 351 | 38.96% | 1020 | 34.02% | 0.000 |
Medical | 1428 | 68.10% | 550 | 61.04% | 1978 | 65.98% | ||
Being vaccinated | No | 103 | 4.91% | 46 | 5.11% | 149 | 4.97% | 0.823 |
Yes | 1994 | 95.09% | 855 | 94.89% | 2849 | 95.03% | ||
Vaccine brand | Oxford/AstraZeneca COVID-19 vaccine | 1200 | 60.18% | 555 | 64.91% | 1755 | 61.60% | 0.021 |
Moderna COVID-19 vaccine | 118 | 5.92% | 59 | 6.90% | 177 | 6.21% | ||
Pfizer-BioNTech COVID-19 vaccine | 218 | 10.93% | 89 | 10.41% | 307 | 10.78% | ||
Sinovac (CoronaVac) | 80 | 4.01% | 26 | 3.04% | 106 | 3.72% | ||
Sinopharm (Verocell) | 306 | 15.35% | 96 | 11.23% | 402 | 14.11% | ||
Sputnik V | 32 | 1.60% | 11 | 1.29% | 43 | 1.51% | ||
Combine | 24 | 1.20% | 17 | 1.99% | 41 | 1.44% | ||
Others | 9 | 0.45% | 1 | 0.12% | 10 | 0.35% | ||
Don’t know | 7 | 0.35% | 1 | 0.12% | 8 | 0.28% | ||
Vaccine dose | 1st dose | 1125 | 56.42% | 412 | 48.19% | 1537 | 53.95% | 0.000 |
2nd dose | 869 | 43.58% | 443 | 51.81% | 1312 | 46.05% | ||